<HashMap><database>biostudies-literature</database><scores/><additional><submitter>DeYoung EG</submitter><funding>National Institute of Allergy and Infectious Diseases</funding><funding>NIAID NIH HHS</funding><funding>NCI NIH HHS</funding><funding>National Institute of General Medical Sciences</funding><funding>NIGMS NIH HHS</funding><funding>Heidelberg Pharma AG</funding><pagination>1358-1368</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10577892</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(10)</volume><pubmed_abstract>TLR7 agonists have significant therapeutic potential in a variety of oncology and autoimmune applications. We recently reported a potent TLR7 selective agonist &lt;b>1&lt;/b> that could be delivered by antibody-drug conjugate (ADC) technology to elicit potent anticancer activity. Herein we report synthetic chemistry and structure-activity relationship studies to develop TLR7 agonists with improved potency for next-generation ADC efforts. We found that the addition of hydrophobic acyl tails to parent compound &lt;b>1&lt;/b> generally resulted in retained or improved TLR7 agonist activity without sacrificing the permeability or the selectivity over TLR8. In contrast, the addition of a simple alkyl tail at the same position resulted in a dramatic loss in potency. Molecular modeling was performed to provi</pubmed_abstract><journal>ACS medicinal chemistry letters</journal><pubmed_title>Synthesis and Optimization of 1-Substituted Imidazo[4,5-&lt;i>c&lt;/i>]quinoline TLR7 Agonists.</pubmed_title><pmcid>PMC10577892</pmcid><funding_grant_id>R01GM140026</funding_grant_id><funding_grant_id>R01 GM140026</funding_grant_id><funding_grant_id>R15 AI149755</funding_grant_id><funding_grant_id>R15 CA227747</funding_grant_id><funding_grant_id>1R15AI149755-01</funding_grant_id><pubmed_authors>Tumey LN</pubmed_authors><pubmed_authors>Handel JP</pubmed_authors><pubmed_authors>Gillen Miller JT</pubmed_authors><pubmed_authors>DeYoung EG</pubmed_authors><pubmed_authors>Reddy MM</pubmed_authors><pubmed_authors>Fang S</pubmed_authors><pubmed_authors>Howe JM</pubmed_authors><pubmed_authors>Wheeler DR</pubmed_authors></additional><is_claimable>false</is_claimable><name>Synthesis and Optimization of 1-Substituted Imidazo[4,5-&lt;i>c&lt;/i>]quinoline TLR7 Agonists.</name><description>TLR7 agonists have significant therapeutic potential in a variety of oncology and autoimmune applications. We recently reported a potent TLR7 selective agonist &lt;b>1&lt;/b> that could be delivered by antibody-drug conjugate (ADC) technology to elicit potent anticancer activity. Herein we report synthetic chemistry and structure-activity relationship studies to develop TLR7 agonists with improved potency for next-generation ADC efforts. We found that the addition of hydrophobic acyl tails to parent compound &lt;b>1&lt;/b> generally resulted in retained or improved TLR7 agonist activity without sacrificing the permeability or the selectivity over TLR8. In contrast, the addition of a simple alkyl tail at the same position resulted in a dramatic loss in potency. Molecular modeling was performed to provi</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Oct</publication><modification>2026-06-03T03:48:16.091Z</modification><creation>2025-04-06T13:21:03.977Z</creation></dates><accession>S-EPMC10577892</accession><cross_references><pubmed>37849530</pubmed><doi>10.1021/acsmedchemlett.3c00260</doi></cross_references></HashMap>